Study: Azacitidine extends survival for pre-leukemia patients

02/18/2009 | Yahoo!

Patients with myelodysplastic syndrome who were injected with azacitidine for six months survived more than nine months longer than those who underwent conventional treatment. The results indicate that the drug "should become the reference treatment" in most patients with the bone marrow disorder, researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL